Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts more than Nifty Smallcap 250 and 7.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vijaya Diagnostic Centre reported strong Q1 FY26 results. Standalone revenue from operations rose ~22.8% YoY to ₹17,484.50 lakhs (vs ₹14,242.32 lakhs in Q1 FY25), while standalone profit after tax grew ~33% to ₹3,838.94 lakhs (vs ₹2,886.31 lakhs). Consolidated revenue grew ~20.4% YoY to ₹18,805.31 lakhs with consolidated PAT up ~22.5% to ₹3,858.90 lakhs. Basic EPS (standalone) improved to ₹3.74 from ₹2.82. No exceptional items were recorded in the quarter. The Board also granted 2,500 additional ESOPs at ₹780 per share under the ESOP 2018 plan and appointed M/s. Balaramakrishna & Associates as Secretarial Auditor for FY26–FY30. The statutory auditor (B S R and Co) issued an unmodified limited review report.
Robust double-digit revenue and profit growth, along with expanding operating margins, signal healthy business momentum and are likely to be viewed positively by shareholders. The proposed ₹2/share dividend and ongoing subsidiary merger (Medinova) are incremental positives for long-term investors.